Company / PP&E (Net)
Merck & Co. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$25.3B
FY2025
5-year range
$19.3B / $25.3B
FY2021-FY2025
Trend
+6.5%
vs FY2024
Sector context
#1 of 193
Health Care
What the data says
Among 193 Health Care companies, Merck & Co. is in the top 1% for pp&e (net). PP&E (Net) has increased for 9 consecutive years, from $12.0B in FY2016 to $25.3B in FY2025.
Based on SEC 10-K filings.
$25.3B in FY2025 with a 5-year CAGR of +8.3%. Ranks 1st among 193 companies in Health Care.
Improved from $23.1B to $25.3B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +5.7%
- 5-Year CAGR
- +8.3%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 193This company $25.3B Sector average $777.6M
▼
+3155.5% above sector average
Key checks
Key Insights
- Merck & Co.'s pp&e (net) has grown for 9 consecutive years.
- 5-year CAGR of +8.3%, indicating consistent growth.
- In FY2025, pp&e (net) increased 6.5% year-over-year.
- Ranks #1 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 29.6%
- Strong return on equity: 36.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.3B | +6.5% |
| FY2024 | $23.8B | +3.2% |
| FY2023 | $23.1B | +7.6% |
| FY2022 | $21.4B | +11.1% |
| FY2021 | $19.3B | +13.4% |
| FY2020 | $17.0B | +18.9% |
| FY2019 | $14.3B | +7.6% |
| FY2018 | $13.3B | +6.8% |
| FY2017 | $12.4B | +3.4% |
| FY2016 | $12.0B | -3.8% |
As of FY2025 · SEC 10-K · Updated Mar 9, 2026